When researchers returned to Zimbabwe several months after the end of a trial involving condom and diaphragm use, they were disappointed to find that condom use - which had risen to 86 percent during the trial - had reduced significantly.
"What happens after trials has always remained very much a mystery, and today, with biomedical prevention that has proved to be partly efficacious, such as the microbicide gel from the CAPRISA trial [which found that a vaginal gel containing tenofovir, an antiretroviral (ARV) drug, was 39 percent effective at reducing women's risk of contracting HIV during sex], it would be interesting to see what happens after the trial," Ariane van der Straten, lead author of a recent study on the issue, told IRIN/PlusNews.
"We were disappointed to see that all the effort and intense counselling provided to participants didn't seem to have a long-lasting effect - in effect, condom use went back to enrolment levels."
Read the rest
[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]
No comments:
Post a Comment